Categories: Healthcare

Diagnostic Radioisotopes Market worth $8.06 billion by 2028 | Top Keyplayers Are Cardinal Health Inc., Sumitomo Heavy Industries Ltd., BWX Technologies Inc., Lantheus Holdings, Curium Pharma

The diagnostic radioisotopes from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Diagnostic Radioisotopes Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –

The diagnostic radioisotopes market size has grown strongly in recent years. It will grow from $5.06 billion in 2023 to $5.54 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to the discovery of radioactivity, the introduction of technetium-99m, clinical applications and research, cold war era and nuclear research, and emergence of positron emission tomography.

The diagnostic radioisotopes market size is expected to see strong growth in the next few years. It will grow to $8.06 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to emerging radioisotope production methods, expanded clinical applications, patient-centered care and safety, point-of-care imaging and environmental sustainability and green chemistry. Major trends in the forecast period include hybrid imaging techniques, theranostics, molecular imaging techniques, the use of cyclotrons or generators, and safety and radiation protection.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/diagnostic-radioisotopes-global-market-report

Scope Of Diagnostic Radioisotopes Market

The Business Research Company’s reports encompass a wide range of information, including:

Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
Drivers: Examination of the key factors propelling market growth.
Trends: Identification of emerging trends and patterns shaping the market landscape.
Key Segments: Breakdown of the market into its primary segments and their respective performance.
Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
Macro Economic Factors: Assessment of broader economic elements impacting the market.

Diagnostic Radioisotopes Market Overview

Market Drivers –

The rising burden of cancer is expected to propel the growth of the diagnostic radioisotopes market going forward. Cancer refers to a disease in which abnormal cells divide uncontrollably and destroy body tissue. The rising burden of cancer is due to lifestyle choices, such as smoking, obesity, lack of physical activity, exposure to carcinogens, genetic predisposition, and environmental factors. Radioisotopes are powerful tools in cancer management, enabling precise diagnosis, targeted treatment, and effective monitoring of cancer progression or response to therapy. For instance, in October 2023, according to a report by the European Commission, a Europe-based governing body, new cancer cases increased by 2.3 % from 2020, reaching 2.74 million in 2022. Similarly, cancer deaths saw a 2.4 % increase compared to 2020. Therefore, the rising burden of cancer is driving the growth of the diagnostic radioisotopes market.

Market Trends –

Major companies operating in the diagnostic radioisotopes market are focused on developing advanced radiopharmaceutical technology to enhance diagnostic accuracy, improve patient outcomes, and broaden the applications of nuclear medicine in healthcare. Advanced radiopharmaceutical technology refers to the development of innovative compounds and techniques for precise imaging and targeted therapy in nuclear medicine. For instance, in March 2022, Bracco Group, an Italy-based diagnostic imaging company, launched Blue Earth Therapeutics, a subsidiary to advance the development of next-generation therapeutic radiopharmaceutical technology. This subsidiary is focused on developing precision-targeted therapeutic radiopharmaceuticals, initially targeting prostate cancer, with plans to expand into additional disease areas in oncology.

The diagnostic radioisotopes market covered in this report is segmented –

1) By Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FluoroDeoxyGlucose (FDG), Rubidium-82, Other Radioisotopes

2) By Imaging Modality: Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Beta Emitters

3) By Application: Oncology, Cardiology, Other Applications

4) By End User: Hospitals, Specialty Clinics, Diagnostic Centers, Academic And Research Institutes, Other End Users

Get an inside scoop of the diagnostic radioisotopes market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16033&type=smp

Regional Insights –

North America was the largest region in the diagnostic radioisotopes market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diagnostic radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –

Major companies operating in the diagnostic radioisotopes market are Cardinal Health Inc., Sumitomo Heavy Industries Ltd., BWX Technologies Inc., Lantheus Holdings, Curium Pharma, Clarity Pharmaceuticals, Bracco Diagnostic Inc., Ion Beam Applications S.A., Nordion Inc., Eckert & Ziegler AG, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Global Medical Solutions Ltd., Isotopia Molecular Imaging Ltd., Cyclopharm Limited, Trasis NV, Orano Med LLC, ARTMS Inc., Radiomedix Inc., Coqu RadioPharmaceuticals Corp., IsoTherapeutics Group LLC

Table of Contents